Key Operational Highlights Q1'FY22

Business outlook remains robust Targeted expansion backed by solid growth visibility to support momentum Continuous focus on new strategic initiatives to elevate performance Domestic: Focus on portfolio diversification with launch of novel offerings CSM Export: R&D focused approach to drive incremental business Efforts to drive strategic initiatives continues PI's product research efforts yielding promising results!! • • • • • Pi Inspired by Science Business outlook remains positive backed by normal monsoon for 3rd year in a row 3 new products expected to be launched in Q2 which would strengthen the position in rice, cotton and horticulture portfolio Products transition to new packaging in ~Q2, to improve efficiency & branding ~6 new molecules planned to be commercialized in FY22. Commissioning of 3 new molecules is under progress Another MPP planned to be made ready by Q2 FY22 Order book continues to remain robust @ $1.5bn with high visibility of sustainable growth for the next 3 years Value-driven strategic acquisition of API & Intermediate business undertaking of Ind- Swift Laboratories Limited and creating a differentiated scale play in pharma • Evaluating & negotiating complementary technology partnerships • Investing in a new R&D facility for deepening our technological capabilities, de- risking current operations and opening up newer opportunities Two promising leads; one novel fungicide and a novel broad spectrum insecticide, having sizable potential market opportunity progressing to development phase Both have shown promising results in the initial evaluations Discussions are underway with global innovators for development partnership Maintain original guidance of >15% revenue growth in FY22 and resolutely progressing on that path 6

View entire presentation